Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.4.0.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net loss $ (11,978) $ (118,037)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 22,199 3,525
Non-cash interest 749 1,056
Amortization of deferred financing costs 37 751
Losses from investments in investees 2,345 1,761
Equity-based compensation – employees and non-employees 17,307 7,382
Revenue from receipt of equity 0 (60)
Realized gain on sale of equity securities 0 (216)
(Gain) loss on conversion of 3.00% convertible senior notes 0 321
Change in fair value of derivative instruments 1,423 49,788
Change in fair value of contingent consideration 1,753 5,175
Deferred income tax (benefit) provision (22,244) 0
Changes in assets and liabilities, net of the effects of acquisitions:    
Accounts receivable (9,924) 71
Inventory (152) (2,390)
Prepaid expenses and other current assets (6,883) 944
Other assets 1,447 (509)
Accounts payable (349) 2,107
Foreign currency measurement (253) 473
Deferred revenue (17,809) 282,238
Accrued expenses and other liabilities 13,126 4,413
Net cash provided by (used in) operating activities (9,206) 238,793
Cash flows from investing activities:    
Investments in investees (250) 0
Capital expenditures (9,812) (363)
Net cash used in investing activities (10,062) (363)
Cash flows from financing activities:    
Proceeds from the exercise of Common Stock options and warrants 2,154 12,712
Cash from non-controlling interest 0 791
Borrowings on lines of credit 5,248 5,158
Repayments of lines of credit (7,349) (4,849)
Net cash provided by financing activities 53 13,812
Effect of exchange rate on cash and cash equivalents 590 (957)
Net increase (decrease) in cash and cash equivalents (18,625) 251,285
Cash and cash equivalents at beginning of period 193,598 96,907
Cash and cash equivalents at end of period 174,973 348,192
SUPPLEMENTAL INFORMATION:    
Interest paid 623 1,568
Income taxes paid, net 1,505 227
Non-cash financing:    
Common Stock options and warrants, surrendered in net exercise 35 14,238
2033 Senior Notes    
Non-cash financing:    
Shares issued upon conversion, amount 0 79,888
OPKO Health Europe    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued $ 313 $ 0